First-in-human phase I study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager in patients with metastatic castration-resistant prostate cancer (mCRPC).
Johanna C. Bendell(Dana-Farber Cancer Institute), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Che‐Leung Law(Seagen (United States)), Ashley E. Ross(St. Jude Children's Research Hospital), Tomasz M. Beer(Exact Sciences (United States)), Aaron Weitzman, Vaishnavi Ganti, Mark N. Stein(Cornell University), Lawrence Fong(UCSF Helen Diller Family Comprehensive Cancer Center), Xīn Gào(Qingdao University), Holger Wesche, Richard J. Austin(San Francisco VA Medical Center), Bryan D. Lemon
Cited by 20
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k